Search results
AstraZeneca reports positive interim data from mantle cell lymphoma trial
Clinical Trials Arena via Yahoo Finance· 1 month agoAstraZeneca has announced positive interim results from the Phase III ECHO clinical trial, which...
Bristol Myers (BMY) Announces CAR T Cell Therapy Breyanzi Data
Zacks via Yahoo Finance· 12 months agoBristol Myers' (BMY) CAR T cell therapy Breyanzi (lisocabtagene maraleucel) shows deep and durable...
FDA Gives Conditional Approval For Eli Lilly's Drug For Rare Blood Cancer
Benzinga via Yahoo Finance· 1 year agoThe FDA approved Eli Lilly And Co's (NYSE: LLY) Jaypirca (pirtobrutinib) for adult patients with...
Bristol Myers Squibb’s Breyanzi gains FDA approval for lymphoma
Pharmaceutical Technology via Yahoo Finance· 1 week agoBristol Myers Squibb (BMS) has received approval from the US Food and Drug Administration for...
US FDA expands use of Bristol's cell therapy to treat rare blood cancer
Reuters via AOL· 1 week ago(Reuters) -Bristol Myers Squibb said on Thursday the U.S. FDA had allowed expanded use of its cell...
Bristol Myers Squibb’s Breyanzi shows promise in B-cell malignancy clinical trials
Clinical Trials Arena via Yahoo Finance· 5 days agoUS-based pharmaceutical company Bristol Myers Squibb (BMS) has published data from three studies in...
Bristol Myers' (BMY) sBLAs for Breyanzi Get FDA Priority Tag
Zacks via Yahoo Finance· 4 months agoBristol Myers' (BMY) two sBLAs for Breyanzi in relapsed/refractory follicular lymphoma and...
Gilead (GILD) Kite Reports Positive Data on CAR T-Cell Therapy
Zacks via Yahoo Finance· 1 year agoGilead Sciences’ GILD Kite announced encouraging three-year follow-up results from the ZUMA-3 study...
FDA approves Eli Lilly's drug for rare blood cancer
Reuters via Yahoo News· 1 year agoThe wholesale cost of the treatment, Jaypirca, will be $21,000 per 30 days for the 200 mg dose, the U.S. drugmaker told Reuters. The Food and Drug...
Adicet (ACET) Stock Rallies 130% in a Month: Here's Why
Zacks via Yahoo Finance· 5 months agoAdicet Bio ACET, a clinical-stage company, develops “off-the-shelf” gamma delta T cell therapies...